Skip to content
HowShorted

Alaunos Therapeutics, Inc. short interest in 2018

In 2018, Alaunos Therapeutics, Inc.'s disclosed short interest ran from 23.32% of shares outstanding on 12 Jan 2018 to 28.59% on 31 Dec 2018, a change of +5.27 percentage points. The year's high was 29.79% on 14 Dec 2018 and its low 21.94% on 31 Jan 2018, averaging 25.79% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 48.49 days on 14 Sep 2018. Full history: Alaunos Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Alaunos Therapeutics, Inc. in 2018

2018 in figures

Start of year
23.32% (12 Jan 2018)
End of year
28.59% (31 Dec 2018)
Change
+5.27 pp
High
29.79% (14 Dec 2018)
Low
21.94% (31 Jan 2018)
Average
25.79%
Highest days to cover
48.49 (14 Sep 2018)
SEC filings marked
7

Every report in 2018

Alaunos Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201823.32%17.77
31 Jan 201821.94%12.59
15 Feb 201824.88%19.05
28 Feb 201823.95%25.95
15 Mar 201824.92%21.7710-K filed, results (8-K)
29 Mar 201825.27%35.57
13 Apr 201825.09%28.63
30 Apr 201825.04%47.46
15 May 201824.29%34.3510-Q filed, results (8-K)
31 May 201824.05%34.93
15 Jun 201824.90%27.45
29 Jun 201825.13%14.25
13 Jul 201824.92%46.75
31 Jul 201825.09%28.92
15 Aug 201826.55%22.3910-Q filed, results (8-K)
31 Aug 201826.37%46.16
14 Sep 201826.34%48.49
28 Sep 201826.57%30.46
15 Oct 201826.57%24.00
31 Oct 201827.49%23.79
15 Nov 201828.11%19.8610-Q filed
30 Nov 201829.78%17.27
14 Dec 201829.79%22.51
31 Dec 201828.59%12.52

See also: Alaunos Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.